RAS is the most frequently mutated oncogene in cancer, with KRAS mutations occurring in nearly one-quarter of all human cancers. RAS mutations impair the ability of RAS to convert from its active ...

Anti-oncogenic drugs - In order to grow, tumor cells produce chemical growth factors by switching on oncogenes. Many tumors rely on a mutation of the RAS oncogene in order to develop. Scientists ...

Problems arise, however, when mutations convert the proto-oncogene to an oncogene, rendering Ras permanently active regardless of the signals the cell receives. How do tumor suppressors differ?

Servier will be responsible for development and global commercialisation of the therapy for several indications.

Thus, Rho family proteins have begun to rival, if not overshadow, interest in their more celebrated cousins, the Ras oncogene proteins. The fascination in Rho family proteins is fueled primarily ...

More information: Andrew Kent et al, A stromal inflammasome Ras safeguard against Myc-driven lymphomagenesis, Nature ...

But as you know, Amgen and Mirati are not the only ones in hot pursuit. At the 1 st RAS- Targeted Drug Discovery Summit Europe, 23 other leading organisations will demonstrate how they are ...

Long-term outcomes of neoadjuvant chemotherapy (NAC) before bladder-sparing chemoradiotherapy (CRT) for patients with nonmetastatic muscle-invasive bladder cancer (MIBC). This is an ASCO Meeting ...